⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79191 | 0.77 | NOS2 (0.33) | — | |
| SCHEMBL5648243 | 0.77 | NOS2 (0.33) | — | |
| SCHEMBL1146008 | 0.72 | — | — | |
| SCHEMBL1146005 | 0.72 | — | — | |
| SCHEMBL10673607 | 0.72 | — | — | |
| SCHEMBL15052633 | 0.72 | CA1 (0.33) | — | |
| SCHEMBL9354204 | 0.70 | — | — | |
| SCHEMBL9001480 | 0.69 | CA1 (0.31) | — | |
| SCHEMBL6917809 | 0.69 | — | — | |
| SCHEMBL9358711 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11980633-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-05-14 | — | — | US | claimed |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-03-24 | — | — | US | claimed |
| US-11110108-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | claimed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | claimed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | claimed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | claimed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | claimed |
| EP-3518931-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-08-07 | — | — | EP | claimed |
| EP-3459942-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-03-27 | — | — | EP | claimed |
| US-20180325898-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | claimed |
| US-10076521-B2 | DNA-PK inhibitors | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2018-09-18 | — | — | US | claimed |
| EP-2841428-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-08-22 | — | — | EP | claimed |
| US-20180193341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-12 | — | — | US | claimed |
| WO-2018064092-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | claimed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | claimed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | claimed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | claimed |
| EP-2841428-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2015-03-04 | — | — | EP | claimed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | claimed |
| US-11980633-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-05-14 | — | — | US | disclosed |
| US-20220088043-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-03-24 | — | — | US | disclosed |
| US-11110108-B2 | Method for treating cancer using a combination of DNA-damaging agents and DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-09-07 | — | — | US | disclosed |
| US-11021465-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-06-01 | — | — | US | disclosed |
| US-11008305-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3459942-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2020-12-30 | — | — | EP | disclosed |
| US-20200109130-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-04-09 | — | — | US | disclosed |
| US-20200062732-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2020-02-27 | — | — | US | disclosed |
| US-10442791-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-10-15 | — | — | US | disclosed |
| US-10391095-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-08-27 | — | — | US | disclosed |
| EP-3518931-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-08-07 | — | — | EP | disclosed |
| EP-3459942-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2019-03-27 | — | — | EP | disclosed |
| US-20180325898-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-11-15 | — | — | US | disclosed |
| US-10076521-B2 | DNA-PK inhibitors | VERTEX PHARAMCEUTICALS INCORPORATED (US) | 2018-09-18 | — | — | US | disclosed |
| EP-2841428-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20180208579-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-26 | — | — | US | disclosed |
| US-20180193341-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2018-07-12 | — | — | US | disclosed |
| WO-2018064092-A1 | METHOD FOR TREATING CANCER USING A COMBINATION OF DNA-DAMAGING AGENTS AND DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-04-05 | — | — | WO | disclosed |
| US-9925188-B2 | DNA-PK inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-27 | — | — | US | disclosed |
| EP-3057959-B1 | DNA-PK INHIBITORS | VERTEX PHARMA (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9878993-B2 | DNA-PK inhibitors for treatment of cancer | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170258789-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-09-14 | — | — | US | disclosed |
| US-9592232-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-03-14 | — | — | US | disclosed |
| US-20160368899-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-22 | — | — | US | disclosed |
| US-20160250212-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-09-01 | — | — | US | disclosed |
| EP-3057959-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2016-08-24 | — | — | EP | disclosed |
| US-9376448-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-28 | — | — | US | disclosed |
| US-9296701-B2 | DNA-PK inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-03-29 | — | — | US | disclosed |
| US-20150111871-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | US | disclosed |
| WO-2015058031-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-04-23 | — | — | WO | disclosed |
| EP-2841428-A1 | DNA-PK INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2015-03-04 | — | — | EP | disclosed |
| US-20140045869-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2014-02-13 | — | — | US | disclosed |
| WO-2013163190-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICAL INCORPORATED (US) | 2013-10-31 | — | — | WO | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |
| US-20130281431-A1 | DNA-PK INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED | 2013-10-24 | — | — | US | disclosed |